Genetic determinants of response to fibroblast growth factor receptor inhibitors in solid tumours

Eur J Cancer. 2017 Aug:81:102-105. doi: 10.1016/j.ejca.2017.04.011. Epub 2017 Jun 15.

Authors

Laura Leroy¹, Sophie Cousin², Antoine Italiano³

Affiliations

¹ University of Bordeaux, Bordeaux, France; Early Phase Trials Unit, Institut Bergonié, Bordeaux, France. Electronic address: [email protected].
² Early Phase Trials Unit, Institut Bergonié, Bordeaux, France. Electronic address: [email protected].
³ University of Bordeaux, Bordeaux, France; Early Phase Trials Unit, Institut Bergonié, Bordeaux, France. Electronic address: [email protected].

PMID: 28623773
DOI: 10.1016/j.ejca.2017.04.011

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aniline Compounds / therapeutic use
Benzamides / therapeutic use
Biomarkers, Pharmacological / analysis
Biomarkers, Tumor / analysis
Biomarkers, Tumor / genetics
Drug Resistance, Neoplasm / genetics*
Female
Humans
Male
Middle Aged
Mutation*
Phenylurea Compounds / therapeutic use
Piperazines / therapeutic use
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use
Quinazolines / therapeutic use
Quinoxalines / therapeutic use
Receptors, Fibroblast Growth Factor / antagonists & inhibitors*
Receptors, Fibroblast Growth Factor / genetics
Retrospective Studies
Treatment Outcome

Substances

AZD4547
Aniline Compounds
Benzamides
Biomarkers, Pharmacological
Biomarkers, Tumor
Phenylurea Compounds
Piperazines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
Quinazolines
Quinoxalines
Receptors, Fibroblast Growth Factor
erdafitinib
infigratinib
derazantinib